Ovarian cancer drug combo trial halted early – what we know

NCT ID NCT05756907

Terminated Disease control Sponsor: Sonnet BioTherapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug combination (SON-1010 plus atezolizumab) in people with advanced solid tumors, especially platinum-resistant ovarian cancer. The goal was to see if the combination was safe and could slow tumor growth. The trial was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR PLATINUM-RESISTANT OVARIAN CANCER

Contacts and locations

Locations

Ashford Cancer Centre Research

Kurralta Park, South Australia, 5037, Australia
Blacktown Mt Druitt Hospital

Blacktown, New South Wales, 2148, Australia
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Sarcoma Oncology Center

Santa Monica, California, 90403, United States
The Border Cancer Hospital

Albury, New South Wales, 2640, Australia
University of Southern California

Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.